Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced that Fujirebio Inc., a Japanese multinational biotechnology company, is using Kinaxis and its AI-powered supply chain orchestration platform Maestro™ to enhance and optimize its supply chain operations.
Fujirebio Inc., a consolidated subsidiary of Fujirebio Holdings Inc., is a global leader in the development, manufacturing and sales of clinical diagnostic reagents and testing equipment. Fujirebio is currently focused on strengthening and expanding its Contract Development and Manufacturing Organization (CDMO) by leveraging high-quality raw materials in the immunology field and advanced reagent development technologies.
To accelerate the company’s growth, Fujirebio needed to strategically link and synchronize its entire supply chain process, which spans raw material production to final product shipment and encompasses a multi-layered and complex set of operations.
“The adoption of Kinaxis is central to building a more flexible and efficient supply chain model,” said Kazuya Saito, division head of SCM division, corporate SCM division at Fujirebio Inc. “This will enable faster strategic decision-making and accelerate our efforts toward transforming our business structure. At the same time, we aim to provide new value to the healthcare industry.”
By implementing the Maestro platform, Fujirebio is working to orchestrate demand, production and procurement planning across its supply chain, enabling fast planning simulations. This will also facilitate the establishment of an S&OP (Sales and Operations Planning) process that accelerates strategic decision-making based on financial data.
“In the healthcare industry, there is a need for advanced planning management that considers manufacturing constraints and manages inventory in both quantity and financial terms. We are pleased to support Fujirebio as they advance strategic decision-making through the use of simulations,” said Phillip Teschemacher, president of APAC at Kinaxis.
